Table 1.

Genomic findings

Gene	Chr	HGVS DNA ref	HGVS Protein ref	Variant type	Predicted effect	Allele frequency	Target coverage	Mutation read count
KLC1–ALK	2	t(2;14)(p23.1;32.33) (hg19 Chr 2:29,223,717:Chr 14:103,673,469)	n/a	KLC1–ALK fusion	Oncogenic, sensitivity to ALK inhibitor	8.09%	5860×	474
ALK	2	c.3521T>G	p.F1174C	Substitution	Crizotinib resistance	0.27%	10,316×	28
ALK	2	c.3522C>A	p.F1174L	Substitution	Crizotinib resistance	0.79%	10,192×	81
ALK	2	c.3522C>G	p.P1174L	Substitution	Crizotinib resistance	3.26%	10,192×	332
ALK	2	c.3806G>C	p.G1269A	Substitution	Crizotinib resistance	0.51%	16,190×	83